Visão geral da indústria global de diagnóstico de cancro cerebral e previsões para 2031 – Análise de mercado e quota de mercado

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Visão geral da indústria global de diagnóstico de cancro cerebral e previsões para 2031 – Análise de mercado e quota de mercado

  • Medical Devices
  • Upcoming Reports
  • Sep 2024
  • Global
  • 350 Páginas
  • Número de tabelas: 220
  • Número de figuras: 60

Global Brain Cancer Diagnostic Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Diagram Período de previsão
2024 –2031
Diagram Tamanho do mercado (ano base )
USD 1.55 Billion
Diagram Tamanho do mercado ( Ano de previsão)
USD 5.21 Billion
Diagram CAGR
%
Diagram Principais participantes do mercado
  • NIHON KOHDEN CORPORATION
  • Canon
  • FUJIFILM Holdings Corporation
  • Neusoft Corporation
  • GE HealthCare

>O mercado global de diagnóstico de cancro cerebral foi avaliado em 1,55 mil milhões de dólares em 2023. O tamanho do mercado está a crescer a um CAGR de 18,90% e prevê-se que atinja os 5,21 mil milhões de dólares até 2031.

Mercado de diagnóstico de cancro cerebral

Visão geral da indústria global do mercado de diagnóstico do cancro cerebral

Uma proliferação celular aberrante e descontrolada no cérebro é designada por tumor cerebral. Pode ser benigno ou canceroso. O tecido cerebral dá origem a tumores cerebrais, que quase nunca se espalham. Eventualmente, o tumor comprime outras estruturas cerebrais, causando danos. A American Brain Tumor Association (ABTA) distingue entre tumores cerebrais primários e secundários. O tecido cerebral dá origem a tumores primários, enquanto outras partes do corpo dão origem a tumores secundários que acabam por se espalhar para o cérebro.

 O relatório de mercado de pesquisa de mercado da Data Bridge fornece detalhes dos desenvolvimentos recentes, regulamentos comerciais, quota de mercado, tendências de mercado com base nas suas segmentações e análises regionais, impacto dos participantes do mercado, análise de oportunidades em termos de bolsas de receitas emergentes, regulamentos de mercado, mercado estratégico. Para mais informações sobre o mercado, contacte a equipa de analistas especializados da Data Bridge Market Research. A nossa equipa irá ajudá-lo a tomar decisões de mercado informadas para alcançar o crescimento do negócio.

Tamanho do mercado global de diagnóstico de cancro cerebral e análise de mercado

Detalhes da métrica do relatório global de diagnóstico de cancro cerebral

Período de previsão

2024-2031

Ano base

2023

Ano histórico

2022 (personalizável 2016-2021)

Unidade de medição

Bilhões de dólares

Ponteiro de dados

Valor de mercado, taxa de crescimento, segmentos de mercado, cobertura geográfica, participantes do mercado e cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui análise especializada aprofundada, epidemiologia do paciente, análise de pipeline , análise de preços e enquadramento regulamentar.

O tipo mais prevalente de tumor primário com origem no tecido glial do cérebro é o glioma. Comparando o glioblastoma multiforme com outros tumores, é de grau superior e cresce mais rapidamente. Existem medicamentos de última geração disponíveis para tratar tumores cerebrais. Durante o período projetado, prevê-se que o aumento dos gastos em I&D farmacêutico alimente o crescimento rentável no mercado mundial de tratamento de tumores cerebrais. A Data Bridge Market Research mergulhou na análise abrangente do mercado e revelou que o Mercado Global de Diagnóstico do Cancro Cerebral está a aumentar a um CAGR de 18,90%. A dimensão do mercado está avaliada em 1,55 mil milhões de dólares em 2023 e deverá crescer até aos 5,21 mil milhões de dólares em 2031.

Dinâmica global do mercado de diagnóstico de cancro cerebral

Motores globais de crescimento do mercado de diagnóstico de cancro cerebral

 Terapias Baseadas em Peptídeos

Os sistemas de administração de fármacos baseados em peptídeos foram introduzidos como resultado do sucesso da terapêutica baseada em peptídeos, que foi demonstrado pela primeira vez pelos tratamentos com insulina. Isto teve um impacto significativo no mercado de tratamento do cancro. Os medicamentos péptidos têm sido utilizados com muito mais frequência no tratamento e diagnóstico do cancro nos últimos anos, e a sua utilização em regimes de quimioterapia aumentou significativamente. Ao melhorar a eficácia das terapias contra o cancro, esta integração impulsiona desenvolvimentos e expansão adicionais no mercado terapêutico contra o cancro baseado em peptídeos.

Natureza diversa dos gliomas

Os gliomas representam uma classe heterogénea de tumores cerebrais derivados de células gliais, e a sua natureza complexa apresenta obstáculos formidáveis ​​tanto para o diagnóstico como para o tratamento. Os seus padrões de crescimento, comportamentos clínicos e características moleculares diferem muito entre eles. Desde tumores de baixo grau e crescimento lento até formas agressivas de alto grau, como os glioblastomas, os gliomas podem assumir muitas formas diferentes. Cada tumor é distinto devido à sua diversidade, que inclui variações nas mutações genéticas, alterações epigenéticas e características histológicas. Como os gliomas são heterogéneos, são necessárias técnicas de diagnóstico específicas e planos de tratamento individualizados. Uma abordagem única é frequentemente insuficiente para satisfazer os requisitos únicos de cada doente e tipo de tumor.

 Investimentos em I&D impulsionam crescimento do mercado

A crescente necessidade de diagnóstico e tratamento eficientes é em grande parte impulsionada pela crescente incidência de tumores cerebrais. A Sociedade Americana de Oncologia Clínica (ASCO) refere que o número anual de novos casos de cancro cerebral primário diagnosticados apenas nos Estados Unidos é de 22.850, representando um aumento de 2,6% na taxa de incidência de tumores cerebrais em relação ao ano anterior . A necessidade de métodos de diagnóstico de ponta e de opções de tratamento adequadas a esta crescente população de doentes está a crescer como resultado do aumento de casos e do envelhecimento da população, que é mais vulnerável aos tumores cerebrais.

Oportunidades globais de crescimento do mercado de diagnóstico de cancro cerebral

Telemedicina transformando o cancro cerebral

Ao permitir consultas remotas e serviços de diagnóstico, os avanços na telemedicina estão a revolucionar o diagnóstico do cancro cerebral. Isto é especialmente útil para áreas desfavorecidas e rurais que têm acesso limitado a cuidados especializados. Os doentes podem obter avaliações profissionais, análises de imagens e interpretações de diagnóstico dos principais especialistas virtualmente através de plataformas de telemedicina. Para além de garantir cuidados rápidos e equitativos aos doentes com cancro cerebral, esta acessibilidade remota alarga o âmbito dos serviços de diagnóstico, estimulando a expansão do mercado e melhorando os resultados dos doentes em áreas anteriormente mal servidas.

Integração da Inteligência Artificial

A utilização de aprendizagem automática e inteligência artificial (IA) para avaliar dados de imagem e prever o comportamento do tumor melhora muito a precisão e a eficiência do diagnóstico do cancro cerebral. Os algoritmos de inteligência artificial (IA) têm a capacidade de processar e interpretar dados de imagens complexos de forma mais rápida e precisa do que os métodos tradicionais. Também podem detetar padrões subtis e anomalias que os revisores humanos podem ignorar. Esta tecnologia permite previsões mais precisas da progressão tumoral e da resposta ao tratamento, além de aumentar a precisão da deteção e caracterização tumoral. Consequentemente, o mercado de diagnóstico do cancro cerebral está a registar crescimento e inovação devido à possibilidade de intervenções mais precoces e mais personalizadas fornecidas por soluções de diagnóstico baseadas em IA.

Desafios globais de crescimento do mercado de diagnóstico de cancro cerebral

Variabilidade do doente

O processo de diagnóstico preciso e tratamento eficaz dos tumores cerebrais é complicado pela sua natureza heterogénea, que inclui os seus diversos tipos, características moleculares variadas e variabilidade na forma como os doentes individuais respondem aos testes de diagnóstico . É um desafio desenvolver soluções de diagnóstico universais que sejam eficientes para todos os doentes devido a esta complexidade. A variabilidade na aparência do tumor na imagem, na resposta aos testes moleculares e na resposta ao tratamento pode resultar da variabilidade do tumor, o que exige abordagens individualizadas e técnicas de diagnóstico especializadas para garantir cuidados precisos e personalizados.

Escassez de profissionais qualificados

A adopção generalizada de tecnologias de diagnóstico de última geração é dificultada por uma grave escassez de pessoal qualificado, especialmente nos países em desenvolvimento, que possa operar equipamentos de diagnóstico sofisticados e interpretar dados complexos. A capacidade de utilizar equipamento sofisticado, como aparelhos de ressonância magnética de alta resolução e sistemas sofisticados de diagnóstico molecular, bem como de analisar imagens complexas e dados genéticos, é dificultada pela escassez de pessoal qualificado. Como resultado, esta escassez torna mais difícil a aplicação dos mais recentes desenvolvimentos diagnósticos nestes domínios, agravando as disparidades na qualidade dos cuidados de saúde e limitando o acesso ao melhor diagnóstico do cancro cerebral.

Restrições globais de crescimento do tamanho do mercado de diagnóstico de cancro cerebral

 Elevado custo das ferramentas de diagnóstico

As tecnologias de diagnóstico avançadas, como o diagnóstico molecular e a ressonância magnética de alta resolução, são dispendiosas, o que torna difícil a sua ampla adoção, especialmente nos países em desenvolvimento e de baixo rendimento. Os custos significativos de equipamento e de manutenção contínua associados a estas tecnologias podem ser inacessíveis para sistemas de saúde com orçamentos apertados. Devido a isto, muitas áreas com financiamento limitado têm dificuldade em obter e aplicar estes diagnósticos de ponta, o que causa diferenças na acessibilidade de ferramentas sofisticadas para diagnosticar o cancro cerebral e reduz o padrão geral de cuidados.

Obstáculos regulatórios

As novas tecnologias de diagnóstico do cancro cerebral devem passar por um longo e complicado processo de aprovação regulamentar que inclui numerosos ensaios clínicos, submissões de dados e revisões de entidades reguladoras. Este processo prolongado, que exige que as empresas cumpram requisitos rigorosos e abordem múltiplas preocupações regulamentares, poderá atrasar a entrada no mercado de soluções inovadoras e aumentar significativamente os custos de desenvolvimento. Os atrasos na aprovação podem impedir o fornecimento atempado de instrumentos de diagnóstico sofisticados, impedindo assim o seu acesso atempado aos doentes e aos prestadores de cuidados de saúde. Isto poderá também impedir o crescimento global do mercado e dificultar o progresso alcançado no diagnóstico do cancro cerebral.

Âmbito e tendências globais do mercado de diagnóstico de cancro cerebral

Visão geral das segmentações do mercado global de diagnóstico de cancro cerebral

Tipo de segmento

Subsegmentos

 Tipo de teste

Teste de imagem, biópsia, punção lombar, testes moleculares, eletroencefalografia, outros

Tipo de cancro

Neuroma Acústico , Astrocitomas , Glioblastoma Multiforme, Meningiomas, Oligodendroglioma , Outros

Faixa etária

Abaixo de 21, 21-34, 35-65, 65 e acima

Utilizador final

Hospitais, clínicas especializadas, centros de diagnóstico e institutos de investigação, centros de cirurgia ambulatória, outros

 Visão principal

  • Os avanços na tecnologia de EEG de alta densidade, utilizando mais elétrodos, melhoram a resolução espacial e a sensibilidade, permitindo uma deteção mais precisa de anomalias relacionadas com o tumor.
  • Os centros de diagnóstico estão a melhorar a caracterização e a precisão dos tumores, integrando técnicas de imagem multimodais, combinando ressonância magnética, PET e tomografia computorizada.
  • A sequenciação de nova geração e o perfil molecular identificam mutações genéticas como IDH1/2 e metilação do promotor MGMT no Glioblastoma Multiforme, permitindo estratégias de tratamento personalizadas e precisas.
  • Identificação e validação de novos biomarcadores específicos para GBM que possam ser utilizados para deteção precoce, prognóstico e monitorização da resposta terapêutica.

Análise regional do mercado global de diagnóstico de cancro cerebral – Tendências de mercado

Visão regional do mercado global de diagnóstico de cancro cerebral

Regiões

Países

Europa

Alemanha, França, Reino Unido, Holanda, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa

APAC

China, Japão, Índia, Coreia do Sul, Singapura, Malásia, Austrália, Tailândia, Indonésia, Filipinas, Resto da Ásia-Pacífico

América do Norte

EUA, Canadá e México

MEA

Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito, Israel, Resto do Médio Oriente e África

Ámérica do Sul

Brasil, Argentina e Resto da América do Sul

Principais insights

  • Investimentos significativos em infraestruturas de saúde e melhorias tecnológicas em países como a China, a Índia e o Japão.
  • A América do Norte possui instalações de saúde altamente desenvolvidas, equipadas com tecnologias de diagnóstico de última geração, como ressonância magnética de alta resolução, tomografias PET e diagnóstico molecular avançado.
  • Alargamento dos serviços de telemedicina para consultas e diagnósticos remotos, aumentando o acesso a cuidados especializados de cancro cerebral, especialmente em zonas desfavorecidas e rurais.
  • Adoção de técnicas avançadas de imagem intraoperatória e sistemas de neuronavegação para orientar intervenções cirúrgicas precisas e melhorar os resultados durante cirurgias de tumores cerebrais.

Principais players globais do mercado de diagnóstico de cancro cerebral

  • NIHON KOHDEN CORPORATION
  • Canon Inc.
  • FUJIFILM Holdings Corporation
  • Neusoft Corporation
  • GE Saúde
  • Koninklijke Philips NV
  • BD
  • FONAR Corp.

 Desenvolvimentos recentes do mercado global de diagnóstico de cancro cerebralParte inferior do formulário

  • Adoção de tecnologias de imagem de ponta em instalações médicas e de investigação de prestígio, como scanners híbridos PET/RM e scanners de ressonância magnética de alto campo (3T e 7T), melhorando a precisão da identificação e caracterização de tumores cerebrais.
  • O líquido cefalorraquidiano (LCR) proveniente de punções lombares é utilizado para realizar ensaios bioquímicos sofisticados e diagnósticos moleculares que melhoram a identificação de marcadores tumorais, mutações genéticas e biomarcadores ligados ao cancro cerebral.

O relatório de mercado da DBMR sobre o Mercado Global de Diagnóstico do Cancro Cerebral leva-o através de informações valiosas que podem contribuir para a tomada de várias decisões de negócios importantes. Com base nos nossos relatórios e experiência de pesquisa, pode criar estratégias de crescimento realistas para o seu negócio.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 EPIDEMIOLOGY

6 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT

7 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS

7.1 REGULATORY SCENARIO IN THE U.S

7.2 REGULATORY SCENARIO IN AUSTRALIA

7.3 REGULATORY SCENARIO IN JAPAN

7.4 REGULATORY SCENARIO IN CHINA

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE

8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER

8.1.3 IMPROVED IMAGING TECHNIQUES

8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS

8.2 RESTRAINTS

8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER

8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES

8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS

8.3 OPPORTUNITIES

8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS

8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC

8.3.3 RISING HEALTHCARE EXPENDITURE

8.4 CHALLENGES

8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS

8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS

9 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE

9.1 OVERVIEW

9.2 IMAGING TEST

9.2.1 CT SCAN

9.2.2 MRI

9.2.3 PET

9.2.4 OTHERS

9.3 MOLECULAR TESTING

9.4 ELECTROENCEPHALOGRAPHY (EEG)

9.5 LUMBAR PUNCTURE

9.6 BIOPSY

9.6.1 OPEN BIOPSY

9.6.2 STEREOTACTIC BIOPSY

9.6.3 NEEDLE BIOPSY

9.6.4 NEUROENDOSCOPY

9.7 OTHERS

10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 GLIOBLASTOMA MULTIFORME

10.3 MENINGIOMAS

10.4 ASTROCYTOMAS

10.5 ACOUSTIC NEUROMA

10.6 OLIGODENDROGLIOMA

10.7 OLIGODENDROGLIOMA

10.8 OTHERS

11 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP

11.1 OVERVIEW

11.2 35-65

11.3 65 AND ABOVE

11.4 BELOW 21

11.5 21-34

12 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.3 SPECIALTY CLINICS

12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES

12.5 AMBULATORY SURGICAL CENTERS

12.6 OTHERS

13 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY REGION

13.1 OVERVIEW

13.2 NORTH AMERICA

13.2.1 U.S.

13.2.2 CANADA

13.2.3 MEXICO

13.3 EUROPE

13.3.1 GERMANY

13.3.2 FRANCE

13.3.3 U.K.

13.3.4 ITALY

13.3.5 SPAIN

13.3.6 RUSSIA

13.3.7 SWITZERLAND

13.3.8 NETHERLANDS

13.3.9 TURKEY

13.3.10 BELGIUM

13.3.11 REST OF EUROPE

13.4 ASIA-PACIFIC

13.4.1 CHINA

13.4.2 JAPAN

13.4.3 INDIA

13.4.4 AUSTRALIA

13.4.5 SOUTH KOREA

13.4.6 THAILAND

13.4.7 SINGAPORE

13.4.8 INDONESIA

13.4.9 MALAYSIA

13.4.10 PHILIPPINES

13.4.11 REST OF ASIA-PACIFIC

13.5 SOUTH AMERICA

13.5.1 BRAZIL

13.5.2 ARGENTINA

13.5.3 REST OF SOUTH AMERICA

13.6 MIDDLE EAST AND AFRICA

13.6.1 SOUTH AFRICA

13.6.2 SAUDI ARABIA

13.6.3 U.A.E.

13.6.4 KUWAIT

13.6.5 EGYPT

13.6.6 REST OF MIDDLE EAST AND AFRICA

14 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

14.3 COMPANY SHARE ANALYSIS: EUROPE

14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15 SWOT ANALYSIS

16 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE

16.1 KONINKLIJKE PHILIPS N.V.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 CANON INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 SIEMENS HEALTHCARE GMBH

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 BD

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 NIHON KOHDEN CORPORATION.

16.5.1 COMPANY SNAPSHOT

16.5.2 RECENT FINANCIALS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 BIOCEPT, INC.

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENT

16.7 BIOMIND

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 CEREBRAL DIAGNOSTIC

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 DXCOVER LIMITED

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 FONAR CORP.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 FUJIFILM CORPORATION

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 GE HEALTHCARE.

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 HITACHI, LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 MINFOUND MEDICAL SYSTEMS CO.,

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENT

16.15 NANTOMICS.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 NEUSOFT CORPORATION

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 SEQUOIA HEALTHCARE.

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT

16.18 STERNMED GMBH

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 THERMO FISHER SCIENTIFIC INC.

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 TIME MEDICAL HOLDING.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

Lista de Tabela

TABLE 1 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 2 GLOBAL IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 GLOBAL IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 4 GLOBAL MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 GLOBAL ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 GLOBAL LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 GLOBAL BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 GLOBAL BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 GLOBAL OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 11 GLOBAL GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 GLOBAL MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 GLOBAL ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 GLOBAL ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 GLOBAL OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 GLOBAL OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 18 GLOBAL 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 GLOBAL 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 GLOBAL BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 GLOBAL 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 23 GLOBAL HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 GLOBAL SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 GLOBAL DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 GLOBAL AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 GLOBAL OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 36 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 37 U.S. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 38 U.S. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 39 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 40 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 41 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 42 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 43 CANADA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 44 CANADA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 45 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 46 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 47 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 48 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 49 MEXICO IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 50 MEXICO BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 51 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 52 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 53 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 54 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 55 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 56 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 57 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 58 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 59 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 60 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 61 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 62 GERMANY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 63 GERMANY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 64 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 65 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 66 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 67 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 68 FRANCE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 69 FRANCE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 70 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 71 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 72 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 73 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 74 U.K. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 75 U.K. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 76 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 77 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 78 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 79 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 80 ITALY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 81 ITALY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 82 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 83 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 84 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 85 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 86 SPAIN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 SPAIN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 88 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 89 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 90 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 91 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 92 RUSSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 93 RUSSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 94 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 95 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 96 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 97 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 98 SWITZERLAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 99 SWITZERLAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 100 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 101 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 102 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 103 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 104 NETHERLANDS IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 NETHERLANDS BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 106 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 107 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 108 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 109 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 110 TURKEY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 111 TURKEY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 112 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 113 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 114 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 115 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 116 BELGIUM IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 117 BELGIUM BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 118 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 119 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 120 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 121 REST OF EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 122 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 123 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 ASIA-PACIFIC IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 125 ASIA-PACIFIC BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 126 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 127 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 128 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 129 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 130 CHINA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 131 CHINA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 132 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 133 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 134 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 135 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 136 JAPAN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 137 JAPAN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 139 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 140 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 141 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 142 INDIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 143 INDIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 144 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 145 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 146 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 147 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 148 AUSTRALIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 149 AUSTRALIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 150 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 151 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 152 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 153 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 154 SOUTH KOREA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 155 SOUTH KOREA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 156 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 157 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 158 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 159 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 160 THAILAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 161 THAILAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 162 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 163 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 164 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 165 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 166 SINGAPORE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 167 SINGAPORE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 168 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 169 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 170 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 171 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 172 INDONESIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 173 INDONESIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 174 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 175 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 176 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 177 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 178 MALAYSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 179 MALAYSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 180 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 181 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 182 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 183 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 184 PHILIPPINES IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 185 PHILIPPINES BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 186 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 187 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 188 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 189 REST OF ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 190 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 191 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 192 SOUTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 193 SOUTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 194 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 195 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 196 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 197 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 198 BRAZIL IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 199 BRAZIL BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 200 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 201 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 202 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 203 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 204 ARGENTINA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 205 ARGENTINA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 206 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 207 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 208 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 209 REST OF SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 210 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 211 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 212 MIDDLE EAST AND AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 213 MIDDLE EAST AND AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 214 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 215 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 216 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 217 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 218 SOUTH AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 219 SOUTH AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 220 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 221 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 222 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 223 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 SAUDI ARABIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 SAUDI ARABIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 226 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 227 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 228 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 229 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 230 U.A.E. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 231 U.A.E. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 232 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 233 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 234 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 235 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 236 KUWAIT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 237 KUWAIT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 238 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 239 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 240 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 241 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 242 EGYPT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 243 EGYPT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 244 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 245 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 246 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 247 REST OF MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

Lista de Figura

FIGURE 1 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID

FIGURE 8 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 12 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 13 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 14 ASIA –PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR FOR BRAIN CANCER DIAGNOSTIC MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET

FIGURE 16 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022

FIGURE 17 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION)

FIGURE 18 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 19 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022

FIGURE 21 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION)

FIGURE 22 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 23 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 24 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022

FIGURE 25 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 26 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 27 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 28 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022

FIGURE 29 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 30 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)

FIGURE 31 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 32 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 33 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY REGION (2022)

FIGURE 34 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY REGION (2023 & 2030)

FIGURE 35 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY REGION (2022 & 2030)

FIGURE 36 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)

FIGURE 37 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 38 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)

FIGURE 39 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)

FIGURE 40 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)

FIGURE 41 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)

FIGURE 42 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 43 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)

FIGURE 44 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)

FIGURE 45 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)

FIGURE 46 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)

FIGURE 47 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 48 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)

FIGURE 49 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)

FIGURE 50 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)

FIGURE 51 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)

FIGURE 52 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 53 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)

FIGURE 54 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)

FIGURE 55 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)

FIGURE 56 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)

FIGURE 57 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 58 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)

FIGURE 59 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)

FIGURE 60 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)

FIGURE 61 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)

FIGURE 62 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)

FIGURE 63 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)

FIGURE 64 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)

FIGURE 65 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The Global Brain Cancer Diagnostic Market is growing at a CAGR 18.90 % and is expected to reach USD 1.84 million in 2024.
The Global Brain Cancer Diagnostic Market is growing CAGR of 18.90 %. It is valued at USD 1.55 billion 2023 and is projected to reach 5.21 billion 2031.
Key drivers include Peptide-Based Therapies, Diverse Nature of Gliomas, R&D Investments Drives Market Growth.
These factors collectively contribute to the rapid expansion of the brain cancer diagnostic market in the APAC region, positioning it as the fastest-growing area globally.
Our TRIPOD analysis involves comprehensive primary as well as secondary research to gather the data that is analyzed using credible data analysis methodologies involving Data Forecast Modelling, Porter’s Five Force Model, Demand Supply Chain Analysis, and Value Change Analysis.